This reinforces our unique ability for multi-mechanism combinations to address ... the Phase 2b PURSUIT trial for AZD0780, our oral PCSK9 inhibitor, and we look forward to sharing the data at ...

Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

Merck & Co., Inc. (NYSE:MRK) is developing an oral PCSK9 inhibitor, enlicitide ... which brings a new mechanism of action for treating wet AMD and diabetic macular edema, a condition with ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in navigating challenges like ...

And a PCSK9 inhibitor is very effective at lowering ... but might be a first-in-class mechanism. Those are things we’re spending a lot of time on.

Merck & Co., Inc. (NYSE:MRK) is advancing the development of enlicitide, an oral PCSK9 inhibitor positioned ... which introduces a new mechanism of action for treating wet AMD and diabetic macular ...

It builds on the Cancer Drugs Fund (CDF), an early access mechanism for many cancer ... his experience with the uptake of NICE-approved PCSK9 inhibitors to lower cholesterol.

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.